A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing's disease
To evaluate the overall efficacy of the treatment regimen of pasireotide alone or in combination with cabergoline in patients who are pasireotide untreated at screening (Group1) • To evaluate the efficacy of pasireotide in combination with cabergoline in patients treated with pasireotide at screening but still with uncontrolled mUFC (Group 2)